Shares of Adaptive Biotechnologies are up 4% or 32c in pre-market at $8.49 after the company announced that it has entered into a translational collaboration with Takeda to use its clonoSEQ Assay to assess minimal residual disease to facilitate the development and commercialization of Takeda’s pipeline of treatments for patients with lymphoid malignancies.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ADPT:
- Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
- Adaptive Biotechnologies announces translational collaboration with Takeda
- Adaptive Biotechnologies terminates COO Mark Adams
- Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
- Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
